| Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. | |
| | |
MedLine Citation:
|
PMID: 16417964 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: We evaluated the efficacy and tolerability of botulinum A toxin (BTX-A) intravesical injections in patients affected by painful bladder syndrome with increased urinary frequency, refractory to conventional treatment modalities. METHODS: Twelve women and two men were prospectively included in the study. Under short general anaesthesia patients were given injections of 200 U of commercially available BTX-A diluted in 20 ml 0.9% NaCl. Injections were performed submucosally in the trigone and bladder floor under cystoscopic control. Voiding chart, the Visual Analog Scale (VAS) for pain, and urodynamics were performed before treatment and 1 and 3 mo afterward. RESULTS: Overall, 12 patients (85.7%) reported subjective improvement at 1 and 3 mo follow-up. The mean VAS score was significantly reduced at 1 and 3 mo after treatment (p<0.05 for both); at the same time points daytime and nighttime urinary frequency significantly decreased (p<0.01 and p<0.05, respectively), and bladder cystometric capacity significantly increased (p<0.01). Two patients reported incomplete bladder emptying. We did not detect any systemic side effects during or after treatment. CONCLUSIONS: The results of this pilot study indicate that BTX-A intravesical injections are effective in the short-term management of painful bladder syndrome. By modulating afferent C-fiber activity within the bladder walls, BTX-A significantly improves urodynamic parameters and reduces bladder pain and urinary frequency. |
| | |
Authors:
|
Antonella Giannantoni; Elisabetta Costantini; Savino M Di Stasi; Maria Cristina Tascini; Vittorio Bini; Massimo Porena |
Related Documents
:
|
11792954 - Appendiceal versus ileal segment for antegrade continence enema. 8709364 - The kock ileal neobladder: updated experience in 295 male patients. 10411034 - Sequential bacillus calmette-guerin and epirubicin versus bacillus calmette-guerin alon... 9705554 - Long-term results of augmentation cystoplasty. 11560384 - Value of angiographic embolisation for the control of major haemorrhage after oesophago... 17703314 - A novel approach for treatment of sacrococcygeal pilonidal sinus: less is more. |
Publication Detail:
|
Type: Journal Article Date: 2006-01-04 |
Journal Detail:
|
Title: European urology Volume: 49 ISSN: 0302-2838 ISO Abbreviation: Eur. Urol. Publication Date: 2006 Apr |
Date Detail:
|
Created Date: 2006-03-13 Completed Date: 2007-07-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7512719 Medline TA: Eur Urol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 704-9 Citation Subset: IM |
Affiliation:
|
Department of Urology, University of Perugia, Italy. agianton@tin.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Intravesical Aged Botulinum Toxin Type A / administration & dosage, therapeutic use* Cystitis, Interstitial / drug therapy* Female Humans Male Middle Aged Neuromuscular Agents / administration & dosage, therapeutic use* Pain Measurement Pilot Projects Prospective Studies Statistics, Nonparametric Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Botulinum Toxin Type A; 0/Neuromuscular Agents |
| Comments/Corrections | |
Comment In:
|
Eur Urol. 2006 Apr;49(4):606-8
[PMID:
16457945
]
Eur Urol. 2006 Apr;49(4):709 [PMID: 17605171 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prostatic infarction involving the urinary sphincter, an association with pyoderma gangrenosum.
Next Document: Identification of novel gamete receptors that mediate sperm adhesion to the egg coat.